Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter—still a dilemma?

類似資料

• MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
  著者:: Hau, Peter, 等
  出版事項: (2007)
• Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
  著者:: Rahman, Mohummad Aminur, 等
  出版事項: (2019)
• MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials
  著者:: Hegi, Monika E., 等
  出版事項: (2018)
• A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
  著者:: Chai, Rui-Chao, 等
  出版事項: (2019)
• Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
  著者:: Alnahhas, Iyad, 等
  出版事項: (2020)